A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals*

Fatty acid amides constitute a large and diverse class of lipid transmitters that includes the endogenous cannabinoid anandamide and the sleep-inducing substance oleamide. The magnitude and duration of fatty acid amide signaling are controlled by enzymatic hydrolysis in vivo. Fatty acid amide hydrolase (FAAH) activity in mammals has been primarily attributed to a single integral membrane enzyme of the amidase signature (AS) family. Here, we report the functional proteomic discovery of a second membrane-associated AS enzyme in humans that displays FAAH activity. The gene that encodes this second FAAH enzyme was found in multiple primate genomes, marsupials, and more distantly related vertebrates, but, remarkably, not in a number of lower placental mammals, including mouse and rat. The two human FAAH enzymes, which share 20% sequence identity and are referred to hereafter as FAAH-1 and FAAH-2, hydrolyzed primary fatty acid amide substrates (e.g. oleamide) at equivalent rates, whereas FAAH-1 exhibited much greater activity with N-acyl ethanolamines (e.g. anandamide) and N-acyl taurines. Both enzymes were sensitive to the principal classes of FAAH inhibitors synthesized to date, including O-aryl carbamates and α-keto heterocycles. These data coupled with the overlapping, but distinct tissue distributions of FAAH-1 and FAAH-2 suggest that these proteins may collaborate to control fatty acid amide catabolism in primates. The apparent loss of the FAAH-2 gene in some lower mammals should be taken into consideration when extrapolating genetic or pharmacological findings on the fatty acid amide signaling system across species.

[1]  A. Saghatelian,et al.  A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. , 2006, Biochemistry.

[2]  B. Cravatt,et al.  Fatty Acid Amide Hydrolase (–/–) Mice Exhibit an Increased Sensitivity to the Disruptive Effects of Anandamide or Oleamide in a Working Memory Water Maze Task , 2006, Journal of Pharmacology and Experimental Therapeutics.

[3]  Y. Maor,et al.  N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.

[5]  B. Cravatt,et al.  Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. , 2005, Chemistry & biology.

[6]  C. Fowler,et al.  Inhibitors of fatty acid amide hydrolase reduce carrageenan‐induced hind paw inflammation in pentobarbital‐treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors , 2005, British journal of pharmacology.

[7]  N. Ueda,et al.  Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. , 2005, Biochimica et biophysica acta.

[8]  Nasreen S Jessani,et al.  A streamlined platform for high-content functional proteomics of primary human specimens , 2005, Nature Methods.

[9]  B. Cravatt,et al.  Structure and function of fatty acid amide hydrolase. , 2005, Annual review of biochemistry.

[10]  Ajit Varki,et al.  Class assignment of sequence-unrelated members of enzyme superfamilies by activity-based protein profiling. , 2005, Angewandte Chemie.

[11]  N. Ueda,et al.  Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase* , 2005, Journal of Biological Chemistry.

[12]  David L. Steffen,et al.  The DNA sequence of the human X chromosome , 2005, Nature.

[13]  Pavel A Pevzner,et al.  Mammalian phylogenomics comes of age. , 2004, Trends in genetics : TIG.

[14]  A. Saghatelian,et al.  Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity , 2004, Journal of Pharmacology and Experimental Therapeutics.

[15]  A. Saghatelian,et al.  Assignment of endogenous substrates to enzymes by global metabolite profiling. , 2004, Biochemistry.

[16]  K. Mackie,et al.  Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension , 2004, Circulation.

[17]  Alan Saghatelian,et al.  Functional disassociation of the central and peripheral fatty acid amide signaling systems. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Cravatt,et al.  Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia , 2004, Pain.

[19]  D. Kendall,et al.  Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors , 2004, British journal of pharmacology.

[20]  B. Cravatt,et al.  Evidence for Distinct Roles in Catalysis for Residues of the Serine-Serine-Lysine Catalytic Triad of Fatty Acid Amide Hydrolase* , 2003, Journal of Biological Chemistry.

[21]  B. Oh,et al.  Characterization of a Novel Ser-cisSer-Lys Catalytic Triad in Comparison with the Classical Ser-His-Asp Triad* , 2003, Journal of Biological Chemistry.

[22]  Dale L Boger,et al.  Discovering potent and selective reversible inhibitors of enzymes in complex proteomes , 2003, Nature Biotechnology.

[23]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[24]  Nasreen S Jessani,et al.  Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. Mendelson,et al.  Deletion of the GABA(A) receptor beta 3 subunit eliminates the hypnotic actions of oleamide in mice. , 2001, NeuroReport.

[26]  J. Walker,et al.  Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain* , 2001, The Journal of Biological Chemistry.

[27]  J. Burbaum,et al.  Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site‐directed probes , 2001, Proteomics.

[28]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[30]  J. Yates,et al.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.

[31]  D. Deutsch,et al.  The fatty acid amide hydrolase (FAAH). , 2002, Chemistry and physics of lipids.

[32]  D. Boger,et al.  Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Cravatt,et al.  Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Mendelson,et al.  The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist. , 1999, Neuroreport.

[35]  J. Walker,et al.  Pain modulation by release of the endogenous cannabinoid anandamide. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  W. Mendelson,et al.  Characterization of the hypnotic properties of oleamide. , 1999, Neuroreport.

[37]  B. Cravatt,et al.  Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. , 1998, Biochemistry.

[38]  G. Lees,et al.  Modulation of GABAA receptors and inhibitory synaptic currents by the endogenous CNS sleep regulator cis‐9,10‐octadecenoamide (cOA) , 1998, British journal of pharmacology.

[39]  A. Gray,et al.  Oleamide potentiates benzodiazepine-sensitive gamma-aminobutyric acid receptor activity but does not alter minimum alveolar anesthetic concentration. , 1998 .

[40]  R. Lerner,et al.  The Sleep-inducing Lipid Oleamide Deconvolutes Gap Junction Communication and Calcium Wave Transmission in Glial Cells , 1997, The Journal of cell biology.

[41]  M. Neal,et al.  Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Söll,et al.  Glu-tRNAGln amidotransferase: a novel heterotrimeric enzyme required for correct decoding of glutamine codons during translation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  B. Cravatt,et al.  Molecular characterization of human and mouse fatty acid amide hydrolases. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[45]  R. Lerner,et al.  Chemical characterization of a family of brain lipids that induce sleep. , 1995, Science.

[46]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[47]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[48]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.